In the first study with six patients with melanoma as reported by Reardon, four had no cancer recurrence at 25 months after vaccination while the remaining two patients had recurrence, but achieved complete tumor regression after subsequent anti-PD-1 therapy [108]. This evidence concerns the gene PDCD1 and melanoma.